Cell transplantation in Parkinson's disease: how can we make it work?
Christian Winkler1, Deniz Kirik, Anders Björklund
1Department of Neurology, Hannover Medical School, 30625 Hannover, Germany. winkler.christian@mh-hannover.de
Abstract:
Previous open-label clinical trials have provided proof of principle that intrastriatal transplants of fetal dopaminergic neurons can induce substantial and long-lasting functional benefits in patients with Parkinson's disease. However, in two recent NIH-sponsored double-blind trials, functional improvements were only marginal and the primary endpoints were not met. Severe off-phase dyskinesias were observed in a significant proportion of the transplanted patients, raising doubts about the viability of the cell-transplantation approach. Here, we discuss the problems raised by the NIH-sponsored trials and point to several shortcomings that might explain the overall poor outcome, and we identify several crucial issues that remain to be resolved to develop cell replacement into an effective and safe therapy.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
EPS and iPS Cells in Disease Research
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Parkinson's Disease: Overview
iPS Cell Differentiation
Parkinson Disease ll: Pathophysiology

